TVTX logo

Travere Therapeutics, Inc. (TVTX) Cash From Financing

Annual CFF:

$139.42M-$79.33M(-36.26%)
December 31, 2024

Summary

  • As of today, TVTX annual cash from financing is $139.42 million, with the most recent change of -$79.33 million (-36.26%) on December 31, 2024.
  • During the last 3 years, TVTX annual cash from financing has fallen by -$92.26 million (-39.82%).
  • TVTX annual cash from financing is now -39.87% below its all-time high of $231.86 million, reached on December 31, 2018.

Performance

TVTX Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherTVTXcash flow metrics

Quarterly CFF:

$1.48M-$2.24M(-60.33%)
June 30, 2025

Summary

  • As of today, TVTX quarterly cash from financing is $1.48 million, with the most recent change of -$2.24 million (-60.33%) on June 30, 2025.
  • Over the past year, TVTX quarterly cash from financing has increased by +$693.00 thousand (+88.62%).
  • TVTX quarterly cash from financing is now -99.36% below its all-time high of $230.96 million, reached on September 30, 2018.

Performance

TVTX Quarterly Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherTVTXcash flow metrics

TTM CFF:

$144.36M+$693.00K(+0.48%)
June 30, 2025

Summary

  • As of today, TVTX TTM cash from financing is $144.36 million, with the most recent change of +$693.00 thousand (+0.48%) on June 30, 2025.
  • Over the past year, TVTX TTM cash from financing has increased by +$144.61 million (+57158.50%).
  • TVTX TTM cash from financing is now -56.15% below its all-time high of $329.24 million, reached on March 31, 2021.

Performance

TVTX TTM Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherTVTXcash flow metrics

Cash From Financing Formula

CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities

TVTX Cash From Financing Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1Y1 Year-36.3%+88.6%+10000.0%
3Y3 Years-39.8%+77.5%-4.0%
5Y5 Years+6812.7%-98.6%+40.5%

TVTX Cash From Financing Highs & Lows

PeriodPeriodAnnual vs HighAnnual vs HighAnnual vs LowAnnual vs LowQuarter. vs HighQuarter. vs HighQuarter. vs LowQuarter. vs LowTTM vs HighTTM vs HighTTM vs LowTTM vs Low
3Y3-Year-39.8%+18.6%-99.3%+332.6%-35.0%>+9999.0%
5Y5-Year-39.8%+6812.7%-99.3%+332.6%-56.1%>+9999.0%
All-TimeAll-Time-39.9%+2548.6%-99.4%+103.7%-56.1%+441.2%

TVTX Cash From Financing History

DateAnnualQuarterlyTTM
Jun 2025
-
$1.48M(-60.3%)
$144.36M(+0.5%)
Mar 2025
-
$3.72M(-97.3%)
$143.66M(+3.0%)
Dec 2024
$139.42M(-36.3%)
$139.12M(>+9900.0%)
$139.42M(>+9900.0%)
Sep 2024
-
$46.00K(-94.1%)
$427.00K(+268.8%)
Jun 2024
-
$782.00K(+249.0%)
-$253.00K(-120.6%)
Mar 2024
-
-$525.00K(-523.4%)
$1.23M(-99.4%)
Dec 2023
$218.75M(+86.1%)
$124.00K(+119.6%)
$218.75M(-0.2%)
Sep 2023
-
-$634.00K(-128.0%)
$219.18M(-1.3%)
Jun 2023
-
$2.27M(-99.0%)
$222.09M(+0.7%)
Mar 2023
-
$217.00M(>+9900.0%)
$220.66M(+87.7%)
Dec 2022
$117.57M(-49.3%)
$551.00K(-75.8%)
$117.57M(-21.7%)
Sep 2022
-
$2.28M(+174.1%)
$150.24M(-0.1%)
Jun 2022
-
$831.00K(-99.3%)
$150.37M(+0.4%)
Mar 2022
-
$113.91M(+243.0%)
$149.84M(-35.3%)
Dec 2021
$231.68M(+81.4%)
$33.21M(+1275.8%)
$231.68M(+3.7%)
Sep 2021
-
$2.41M(+696.7%)
$223.51M(+1.3%)
Jun 2021
-
$303.00K(-99.8%)
$220.75M(-33.0%)
Mar 2021
-
$195.75M(+681.8%)
$329.24M(+157.8%)
Dec 2020
$127.71M(+6248.9%)
$25.04M(+7295.1%)
$127.71M(+24.3%)
Sep 2020
-
-$348.00K(-100.3%)
$102.77M(+0.4%)
Jun 2020
-
$108.80M(+1984.5%)
$102.38M(+1619.0%)
Mar 2020
-
-$5.77M(-6176.8%)
-$6.74M(-224.5%)
Dec 2019
-$2.08M(-100.9%)
$95.00K(+112.9%)
-$2.08M(-26.1%)
Sep 2019
-
-$738.00K(-127.8%)
-$1.65M(-100.7%)
Jun 2019
-
-$324.00K(+70.8%)
$230.05M(-1.5%)
Mar 2019
-
-$1.11M(-311.4%)
$233.46M(+0.7%)
Dec 2018
$231.86M(+4158.3%)
$525.00K(-99.8%)
$231.86M(-0.4%)
Sep 2018
-
$230.96M(+7386.4%)
$232.70M(+2970.3%)
Jun 2018
-
$3.08M(+214.2%)
$7.58M(+144.2%)
Mar 2018
-
-$2.70M(-298.5%)
$3.10M(-43.0%)
Dec 2017
$5.45M
$1.36M(-76.7%)
$5.45M(+294.1%)
Sep 2017
-
$5.83M(+519.8%)
-$2.81M(+39.0%)
Jun 2017
-
-$1.39M(-285.0%)
-$4.60M(+10.3%)
DateAnnualQuarterlyTTM
Mar 2017
-
-$361.00K(+94.8%)
-$5.13M(+9.9%)
Dec 2016
-$5.69M(-105.7%)
-$6.89M(-270.6%)
-$5.69M(-499.9%)
Sep 2016
-
$4.04M(+310.6%)
$1.42M(+103.4%)
Jun 2016
-
-$1.92M(-107.0%)
-$42.31M(-7.6%)
Mar 2016
-
-$926.00K(-504.4%)
-$39.33M(-139.0%)
Dec 2015
$100.77M(+5.7%)
$229.00K(+100.6%)
$100.77M(+0.8%)
Sep 2015
-
-$39.70M(-3803.7%)
$100.00M(-30.2%)
Jun 2015
-
$1.07M(-99.2%)
$143.25M(-26.9%)
Mar 2015
-
$139.17M(>+9900.0%)
$195.87M(+105.5%)
Dec 2014
$95.32M(+228.9%)
-$534.00K(-115.1%)
$95.32M(-0.0%)
Sep 2014
-
$3.54M(-93.4%)
$95.32M(-15.6%)
Jun 2014
-
$53.69M(+39.0%)
$112.91M(+90.7%)
Mar 2014
-
$38.62M(+7388.9%)
$59.22M(+104.3%)
Dec 2013
$28.98M(+553.1%)
-$529.80K(-102.5%)
$28.98M(-1.8%)
Sep 2013
-
$21.13M(>+9900.0%)
$29.51M(+252.3%)
Jun 2013
-
$0.00(-100.0%)
$8.38M(0.0%)
Mar 2013
-
$8.38M(>+9900.0%)
$8.38M(>+9900.0%)
Dec 2012
$4.44M(>+9900.0%)
-
-
Nov 2011
-
$0.00(0.0%)
$0.00(0.0%)
Aug 2011
-
$0.00(0.0%)
$0.00(0.0%)
May 2011
-
$0.00(0.0%)
$0.00(0.0%)
Feb 2011
$0.00(0.0%)
$0.00(0.0%)
$0.00(0.0%)
Nov 2010
-
$0.00(0.0%)
$0.00(0.0%)
Aug 2010
-
$0.00(0.0%)
$0.00(0.0%)
May 2010
-
$0.00(0.0%)
$0.00(0.0%)
Feb 2010
$0.00(-100.0%)
$0.00(0.0%)
$0.00(0.0%)
Nov 2009
-
$0.00(0.0%)
$0.00(0.0%)
Aug 2009
-
$0.00(0.0%)
$0.00(0.0%)
May 2009
-
$0.00(0.0%)
$0.00(-100.0%)
Feb 2009
$25.00K(>+9900.0%)
$0.00(0.0%)
$25.00K(0.0%)
Nov 2008
-
$0.00(0.0%)
$25.00K(0.0%)
Aug 2008
-
$0.00(-100.0%)
$25.00K(0.0%)
May 2008
-
$25.00K
$25.00K
Feb 2008
$0.00
-
-

FAQ

  • What is Travere Therapeutics, Inc. annual cash from financing?
  • What is the all-time high annual cash from financing for Travere Therapeutics, Inc.?
  • What is Travere Therapeutics, Inc. annual cash from financing year-on-year change?
  • What is Travere Therapeutics, Inc. quarterly cash from financing?
  • What is the all-time high quarterly cash from financing for Travere Therapeutics, Inc.?
  • What is Travere Therapeutics, Inc. quarterly cash from financing year-on-year change?
  • What is Travere Therapeutics, Inc. TTM cash from financing?
  • What is the all-time high TTM cash from financing for Travere Therapeutics, Inc.?
  • What is Travere Therapeutics, Inc. TTM cash from financing year-on-year change?

What is Travere Therapeutics, Inc. annual cash from financing?

The current annual cash from financing of TVTX is $139.42M

What is the all-time high annual cash from financing for Travere Therapeutics, Inc.?

Travere Therapeutics, Inc. all-time high annual cash from financing is $231.86M

What is Travere Therapeutics, Inc. annual cash from financing year-on-year change?

Over the past year, TVTX annual cash from financing has changed by -$79.33M (-36.26%)

What is Travere Therapeutics, Inc. quarterly cash from financing?

The current quarterly cash from financing of TVTX is $1.48M

What is the all-time high quarterly cash from financing for Travere Therapeutics, Inc.?

Travere Therapeutics, Inc. all-time high quarterly cash from financing is $230.96M

What is Travere Therapeutics, Inc. quarterly cash from financing year-on-year change?

Over the past year, TVTX quarterly cash from financing has changed by +$693.00K (+88.62%)

What is Travere Therapeutics, Inc. TTM cash from financing?

The current TTM cash from financing of TVTX is $144.36M

What is the all-time high TTM cash from financing for Travere Therapeutics, Inc.?

Travere Therapeutics, Inc. all-time high TTM cash from financing is $329.24M

What is Travere Therapeutics, Inc. TTM cash from financing year-on-year change?

Over the past year, TVTX TTM cash from financing has changed by +$144.61M (+57158.50%)
On this page